Visus Therapeutics raises $36M from J&J’s VC arm, others to develop eye drop that treats presbyopia – GeekWire
Visus Therapeutics, a Seattle-based startup developing a presbyopia-correcting eye drop, raised $36 million. Johnson & Johnson Innovation, the venture capital arm of J&J, invested in the Series A round, in addition to RTW Investments, LP, Wille AG, and existing backers.
The company’s lead asset, BRIMOCHOL, is a once-daily eye drop that aims to treat presbyopia, a vision condition caused by aging that can make tasks such as reading difficult. It affects about 123 million adults in the U.S., according to the company. Existing treatments include glasses, contact lenses, or surgery.
Founded in 2019, Visus is led by CEO Ben Bergo, who previously co-founded Lumos Diagnostics and Seattle-based Nohla Therapeutics. He was most recently an exec at Planet Innovation.